Phase II study of patients with metastatic nonsmall cell carcinoma of the lung treated with paclitaxel by 3-hour infusion

Cancer

Volumn 79, Issue 4, 1997, Pages 724-729

  Tester, William J ^a   Jin, Pamela Y ^a   Reardon, Deborah H ^a   Cohn, Jeffrey B ^a   Cohen, Martin H ^a  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

clinical trial; FACT L; lung carcinoma; nonsmall cell; paclitaxel; quality of life

Indexed keywords

CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; POLYETHYLENE; POLYVINYLCHLORIDE;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG INFUSION; FEMALE; FUNCTIONAL ASSESSMENT; GRANULOCYTOPENIA; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; MYALGIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SENSORY NEUROPATHY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; QUALITY OF LIFE; SURVIVAL RATE;

EID: 0031057464     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970215)79:4<724::AID-CNCR9>3.0.CO;2-D     Document Type: Article

References (19)

1. Ettinger DS. Metastatic non-small cell lung cancer. Lung Cancer 1993;9:569-70.
2. Cohen MH. Chemotherapy of non-small cell lung cancer. In: Shields TW. General thoracic surgery. 4th edition. Malvern, PA: Williams & Wilkins, 1994:1229-40.
3. Feigal EG, Christian M, Cheson B, Grever M, Friedman MA. New chemotherapeutic agents in non-small-cell lung cancer. Semin Oncol 1993;20:185-201.
4. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199-220.
5. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992;19:646-62.
6. Murphy WK, Fossella FV, Winn RL, Shin DM, Hynes HE, Gross HM, et al. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993;185:384-8.
7. Chang A, Kim K, Click J, Anderson T, Karp D, Johnson D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer lnst 1993;85:388-94.
8. Strauman JJ. Symptom distress in patients receiving Phase I chemotherapy with taxol. Oncol Nurs Forum 1986;13:40-3.
9. Cella DF, Tulsky DS, Gray G, Sarafian G, Linn E, Bonomi A, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Owcol 1993;11:570-9.
10. Eisenhauer EA, ten Bokkel Huiniink WW, Swenerton KD, Giarmi L, Myles J, van der Burg MEL, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-66.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Stat Assoc 1958:53:457-81.
12. Gatzemeier U, Heckmayer M, Neuhauss R, Schluter I, von Pawel J, Wagner H, et al. Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial. Semin Oncol 1995;22(6 Suppl 15):24-8.
13. Hainsworth JD, Thompson DS, Greco FA. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol 1995;13:1609-14.
14. Millward MJ, Bishop JF, Friedlander M, Levi JA, Goldstein D, Olver IN, et al. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell Lung cancer. J Clin Oncol 1996;14:142-8.
15. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Clavel M, Seeber S, et al. Randomized trial of two doses of taxol in metastatic breast cancer: an interim analysis [meeting abstract]. PTOC Am Soc Clin Oncol 1993;12:A42.
16. Ellis PA, Smith IE, Hardy JR, Nicholson MC, Talbot DC, Ashley SE, et al. Symptom relief with MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in advanced non-small cell lung cancer. Br J Cancer 1995;71:366-70.
17. Hardy JR, Noble T, Smith IE. Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer 1989;160:764-6.
18. Seidman AD, Portenoy R, Yao T-J, Lepore J, Mont EK, Kortmansky J, et al. Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J Natl Cancer Inst 1995;87:1316-22.
19. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860-70.